Chemotherapeutic advances in pancreatic cancer

Current Oncology Reports

Volumn 5, Issue 3, 2003, Pages 219-226

  Berlin, Jordan D ^a   Rothenberg, Mace L ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DEXVERAPAMIL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; EXATECAN; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; LIPOSOME; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLEVITREXED; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RUBITECAN; TOPOTECAN; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; FEBRILE NEUTROPENIA; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; PANCREAS CANCER; PANCREAS RESECTION; REVIEW; SEPSIS; TREATMENT OUTCOME; ADJUVANT THERAPY; METASTASIS; PANCREAS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 0042736473     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0113-8     Document Type: Review

References (59)

1. Burris HA, III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
2. Tempero M, Plunkett W, Ruiz van Haperen V, et al.: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma [abstract]. Proc ASCO 1999, 18:273a.
3. Maisey, N, Chan I, Cunningham D, et al.: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU)with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002, 20:3130-3136.
4. Ducreux M, Rougier P, Pignon J-P, et al.: A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002, 13:1185-1191.
5. Cartwright TH, Cohn A, Varkey JA, et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160-164.
6. Okada S, Okusaka T, Ueno H, et al.: A phase II and pharmacokinetic trial of S-1 in paitents with advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2002, 21:682a.
7. Miller KD, Picus J, Blanke C, et al.: Phase II study of the multi-targeted antifolate LY 231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000, 11:101-103.
8. Smith DB, Gallagher N, Garnett S: A phase II/III trial of efficacy and tolerability of ZD9331 vs gemcitabine in pancreatic cancer [abstract]. Proc ASCO 2002, 21:144a.
9. Yip D, Halford S, Karapetis C, et al.: A phase II trial of Caelyx (liposomal doxorubicin, Doxil) in the treatment of advanced pancreatic carcinoma [abstract]. Proc ASCO 1999, 18:306a.
10. Wils J, Bleiberg H, Blijham G, et al.: Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985, 21:191-194.
11. Topham C, Glees J, Coombes RC: Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Oncology 1993, 50(Suppl 1):78-83.
12. Kornek G, Raderer M, Schenk T et al.: Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer 1995, 76:1356-1362.
13. Wils JA, Kok T, Wagener DJ, et al.: Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993, 9A:203-204.
14. Rougier P, Ducreux M, Ould Kaci M, et al.: Randomized phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC) [abstract]. Proc ASCO 2000, 19:262a.
15. Stevenson JP, Scher RM, Kosierowski R, et al.: Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998, 34:1358-1362.
16. Stehlin JS, Giovanella BC, Natelson EA, et al.: A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999, 14:821-831.
17. Rivkin S, Burris H, III, Gerstein H, et al.: A phase II study of rubitecan (RFS 2000, 9NC, 9-nitro-20(S)-camptothecin) in patients with refractory pancreatic cancer [abstract]. Proc ASCO 2000, 19:262a.
18. D'Adamo D, Hammond L, Donehower R, et al.: Final results of a phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer [abstract]. Proc ASCO 2001, 20:134a.
19. Wagener DJT, Verdonk HER, Dirix LY, et al.: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995, 6:129-132.
20. Whitehead RP,Jacobson J,Brown TD,et al.: Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.J Clin Oncol 1997,15:24142419.
21. De Forni M, Rougier Ph, Adenis A, et al.: Phase II study of Taxotere (RP 56976, docetaxel) in locally advanced and/or metastatic pancreatic cancer [abstract]. Ann Oncol 1994, 5(Suppl 5):202.
22. Okada S, Sakata Y, Matsuno S, et al.: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer 1999, 80:438-443.
23. Berlin JD, Adak S, Vaughn DJ, et al.: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group study (E3296). Oncology 2000, 58:215-218.
24. Hidalgo M, Castellano D, Paz-Ares L, et al.: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999, 17:585-592.
25. Marantz A, Almira E, et al.: Phase II trial of gemcitabine (GEM), 5-fluorouracil (5-FU) and leucovorin (IV) in advanced pancreatic cancer [abstract]. Eur J Cancer 1999, 35:S157.
26. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002, 20:3270-3275.
27. Kindler HL, Dugan W, Hochster H, et al.: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine [abstract]. Proc ASCO 2002, 21:125a.
28. Heinemann V, Wilke H, Mergenthaler HG, et al.: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000, 11:1399-1403.
29. Philip PA, Zalupski M, Vaitvkevicius VK, et al.: Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Cancer 2001, 92:569-577.
30. Colucci G, Giuliani F, Gebbia V, et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meidionale. Cancer 2002, 94:902-910.
31. Wang X-Y, Ni Q-X, Jin M-L, et al.: Gemcitabine versus gemcitabine plus cisplatin as first-line treatment in Chinese patients with locally advanced pancreatic cancer: a multicenter randomized study [abstract]. Proc ASCO 2002, 21:616a.
32. Louvet C, Andre T, Lledo G, et al.: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002, 20:1512-1518.
33. Alberts SR, Townley P, Cha SS, et al.: Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) phase II study [abstract]. Proc ASCO 2002, 21:126a.
34. Rocha Lima CMS, Savarese D, Bruckner H, et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002, 20:1182-1191.
35. Shepard RC, Levy D, Stuart K, et al.: Pancreatic cancer: biweekly gemcitabine/docetaxel chemotherapy [abstract]. Proc ASCO 2001, 20:154a.
36. Stathopoulos GP, Mavroudis D, Tsavaris N, et al.: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001, 12:101-103.
37. Ryan DP, Kulke MH, Fuchs CS, et al.: A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer. Cancer 2002, 94:97-103.
38. Lutz, MP, Ducreux M, Wagener T, et al.: Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group [abstract]. Proc ASCO 2002, 21:498a.
39. Hoffman JP, McGinn CJ, Szarka C, et al.: A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized, resectable pancreatic adenocarcinoma [abstract]. Nac ASCO 1998, 17:283a.
40. Epelbaum R, Rosenblatt E, Nasrallah S, et al.: A phase II study of gemcitabine (GEM) combined with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer [abstract]. Proc ASCO 2000, 19:265a.
41. Blackstock AW, Bernard SA, Richards F, et al.: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999, 17:2208-2212.
42. McGinn CJ, Zalupski MM, Shureiqi I, et al.: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001, 19:4202-4208.
43. Talamonti MS, Catalano PJ, Vaughn DJ, et al.: Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000, 18:3384-3389.
44. Aitken CL, Safar AM, Recht A, Stuart KE: Phase I trial of gemcitabine, cisplatin (CDDP) and external beam radiation therapy (EBRT) for pancreatic cancer [abstract]. Proc ASCO 2002, 21:2221a.
45. Safran H, Moore T, Iannitti D, Dipitrello T, et al.: Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Rad Oncol Biol Phys 2001, 49:1275-1279.
46. Kemp KR, Liehr JG, Giovanella B: Combined radiation and 0-nitrocamptothecin (Rubitecan) in the treatment of locally advanced pancreatic cancer. Ann N Y Acad Sci 2000, 922:320-323.
47. Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
48. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999, 230:776-784.
49. Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001, 358:1576-1585.
50. Allen AM, Zalupski MM, Eckhauser F, et al.: A phase I trial of radiation (RT) dose escalation with concurrent full dose gemcitabine (GEM) following resection of pancreatic cancer [abstract]. Proc ASCO 2002, 21:549a.
51. Hoffman JP, Lipsitz S, Pisansky T et al.: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:317-323.
52. Pisters PWT, Abbruzzesse JL, Janjan NA, et al.: Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998, 16:3843-3850.
53. Wolff RA, Evans DB, Crane CH, et al.: Initial results of preoperative gemcitabine (GEM)-based chemotadiation for resectable pancreatic adenocarcinoma [abstract]. Proc ASCO 2002, 21:516.
54. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447-3455.
55. Bramhall SR, Schulz J, Nemunaitis J, et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in paitents with advanced pancreatic cancer. Br J Cancer 2002, 87:161-167.
56. Cohen SJ, Ho L, Ranganathan S, et al.: Phase II and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma [abstract]. Proc ASCO 2002, 21:137a.
57. Macdonald JS, Chansky K, Whitehead R, et al.: A phase II study of farnesyl trasferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study [abstract]. Proc ASCO 2002, 21:138a.
58. Van Cutsem E, Karasek P, Oettle H, et al.: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) [abstract]. Proc ASCO 2002, 21:130a.
59. Abbruzzesse JL, Rosenberg A, Xiong Q, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab, (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc ASCO 2001, 20:130a.